Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note

New diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs help control diabetes and promote weight loss by altering taste and reducing hunger, some users experience a loss of enjoyment in eating and even develop food anxieties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qipXT2j
via IFTTT

Read More

Max Healthcare to nearly double capacity to 9,500 beds by 2028 after strong quarterly growth

Max Healthcare Institute aims to nearly double its bed capacity to 9,500 by 2028 through brownfield and greenfield expansions, following a 35% increase to 5,000 beds last year. The company reported a 27% jump in first-quarter revenue to Rs 2,574 crore and a 17% rise in net profit to Rs 345 crore, driven by higher occupancy and international patient revenue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tES5J9n
via IFTTT

Read More

Cohance Lifesciences announces $10 million investment in US-based arm

Cohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solutions. This investment aims to support innovators from early development through late-phase clinical supply. Additionally, Cohance is investing Rs 23 crore in a new oligonucleotide building block manufacturing facility in Hyderabad, part of a broader capacity expansion program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G6moSWY
via IFTTT

Read More

From burden to breakthrough: Reimagining the #WeightofDiabetes through meaningful conversations with your doctor

Effectively managing type 2 diabetes involves more than just medication; it requires open communication with healthcare providers to address weight, heart health, and emotional well-being. Proactive conversations can clarify confusion, uncover barriers, and empower individuals to take charge of their health, preventing crises and promoting resilience through personalized care and support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n6QNrjO
via IFTTT

Read More

Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million

Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tpuhbM4
via IFTTT

Read More

Lupin ties up with Sandoz to commercialise biosimilar product

Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling commercialization in the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will manufacture the product and manage regulatory submissions. Sandoz also gains exclusive rights for commercialization in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9LHTCSq
via IFTTT

Read More

Chemists seek ban on quick commerce sale of prescription drugs

The All India Organisation of Chemists and Druggists (AIOCD) has appealed to Amit Shah. They want immediate action against e-pharmacies and quick commerce platforms. These platforms are selling prescription medicines online. AIOCD says this poses a public health risk. They are concerned about drug abuse, especially among young people. AIOCD also highlights the issue of ghost prescriptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XILAdwq
via IFTTT

Read More